OptiScan Imaging Limited
ABN 81 077 771 987

ASX Announcement
12 November 2021

Completion of imaging for Optiscan's Melbourne based Breast Cancer Margin Assessment Trial

Optiscan Imaging Limited (ASX: OIL) ('the Company' or 'Optiscan') is pleased to advise that it has completed the patient recruitment and imaging component of its breast cancer margin assessment trial (ex vivo study) at Royal Melbourne Hospital, Frances Perry House and Epworth Hospital with imaging of 42 breast cancer lumpectomy samples plus associated cavity shaves from 38 patients undertaken during the course of surgery.

The analysis of these images captured with Optiscan's unique, confocal, endomicroscopic technology is underway including comparisons with post-operative histopathology examination (the current standard of care). The Company looks forward to providing a detailed presentation to shareholders at its upcoming Annual General Meeting.

A key goal of the trial is to assess whether by using Optiscan's technology, cancerous tumour cells can be detected at the margin of the excised specimen while the surgery is on-going, providing the opportunity for further cancerous tissue to be removed. This would reduce the requirement for repeat surgery (currently 20 to 30% of lumpectomy patients) with less emotional trauma, physical pain and costs for patient and hospital. The current standard of care can mean that results indicating whether a second surgery is required to remove this additional cancerous tissue can take a number of days.

For investor queries, please contact:
Darren Lurie
Managing Director – Optiscan Imaging Limited
E: dlurie@optiscan.com

This announcement has been authorised for release by the Board of OIL.

About Optiscan

Optiscan is a global leader in the development of microscopic imaging and related technologies for screening, surgery and medical research. Based in Melbourne, Australia, Optiscan has developed and patented endomicroscopic technology which enables real-time, 3D, 'in vivo' imaging of human tissue at the cellular level with applications for cancer screening and surgical margin determination. Optiscan's technology has the capability to improve patient welfare, reduce hospital costs, improve accuracy and reduce the need for multiple procedures. The technology is approved for use in brain surgery and is involved in a number of oral cancer and breast cancer studies.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate", "believe", "could", "estimate", "expect", "future", "intend", "may", "opportunity", "plan", "potential", "project", "seek", "will" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

For personal use only